Search Page

1

Cardiovascular Morbidity in a Randomized Trial Comparing GnRH Agonist and GnRH Antagonist among Patients with Advanced Prostate Cancer and Preexisting Cardiovascular Disease.

Margel D, Peer A, Ber Y, Shavit-Grievink L, Tabachnik T, Sela S, Witberg G, Baniel J, Kedar D, Duivenvoorden WCM, Rosenbaum E, Pinthus JH. Margel D, et al. Among authors: Pinthus JH. J Urol. 2019 Dec;202(6):1199-1208. doi: 10.1097/JU.0000000000000384. Epub 2019 Jun 12. J Urol. 2019. PMID: 31188734 Clinical Trial.

Cite

Share

2

Glucose impairments and insulin resistance in prostate cancer: the role of obesity, nutrition and exercise.

Di Sebastiano KM, Pinthus JH, Duivenvoorden WCM, Mourtzakis M. Di Sebastiano KM, et al. Among authors: Pinthus JH. Obes Rev. 2018 Jul;19(7):1008-1016. doi: 10.1111/obr.12674. Epub 2018 Mar 24. Obes Rev. 2018. PMID: 29573216 Review.

Cite

Share

3

Editorial Comment.

Pinthus JH. Pinthus JH. J Urol. 2018 Sep;200(3):580. doi: 10.1016/j.juro.2018.03.159. Epub 2018 Jun 11. J Urol. 2018. PMID: 29902426 No abstract available.

Cite

Share

4

Thromboembolism in Patients with Bladder Cancer: Incidence, Risk Factors and Prevention.

Zareba P, Duivenvoorden WCM, Pinthus JH. Zareba P, et al. Among authors: Pinthus JH. Bladder Cancer. 2018 Apr 26;4(2):139-147. doi: 10.3233/BLC-170146. Bladder Cancer. 2018. PMID: 29732385 Free PMC article. Review.

Cite

Share

5

The contemporary role of lymph node dissection in the management of renal cell carcinoma.

Zareba P, Pinthus JH, Russo P. Zareba P, et al. Among authors: Pinthus JH. Ther Adv Urol. 2018 Aug 20;10(11):335-342. doi: 10.1177/1756287218794094. eCollection 2018 Nov. Ther Adv Urol. 2018. PMID: 30344645 Free PMC article. Review.

Cite

Share

6

Outcomes of trimodality bladder-sparing therapy for muscle-invasive bladder cancer.

Nguyen EK, Yu H, Pond G, Shayegan B, Pinthus JH, Kapoor A, Mukherjee SD, Neville A, Lalani AA, Hotte SJ, Corbett TB, Dayes IS, Lukka HR. Nguyen EK, et al. Among authors: Pinthus JH. Can Urol Assoc J. 2020 Apr;14(4):122-129. doi: 10.5489/cuaj.5945. Epub 2019 Nov 5. Can Urol Assoc J. 2020. PMID: 31702551 Free PMC article.

Cite

Share

7

Reply By Authors.

Margel D, Peer A, Ber Y, Shavit-Grievink L, Tabachnik T, Sela S, Witberg G, Baniel J, Kedar D, Duivenvoorden WCM, Rosenbaum E, Pinthus JH. Margel D, et al. Among authors: Pinthus JH. J Urol. 2019 Dec;202(6):1208. doi: 10.1097/01.JU.0000581976.09106.a4. Epub 2019 Sep 5. J Urol. 2019. PMID: 31487209 No abstract available.

Cite

Share

8

Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism?

Zareba P, Duivenvoorden W, Leong DP, Pinthus JH. Zareba P, et al. Among authors: Pinthus JH. Ther Adv Urol. 2016 Apr;8(2):118-29. doi: 10.1177/1756287215617872. Epub 2015 Nov 30. Ther Adv Urol. 2016. PMID: 27034724 Free PMC article. Review.

Cite

Share

9

The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy.

Crawford ED, Schally AV, Pinthus JH, Block NL, Rick FG, Garnick MB, Eckel RH, Keane TE, Shore ND, Dahdal DN, Beveridge TJR, Marshall DC. Crawford ED, et al. Among authors: Pinthus JH. Urol Oncol. 2017 May;35(5):183-191. doi: 10.1016/j.urolonc.2017.01.025. Epub 2017 Mar 18. Urol Oncol. 2017. PMID: 28325650 Free article. Review.

Cite

Share

10

Endoplasmic reticulum protein ERp46 in prostate adenocarcinoma.

Duivenvoorden WCM, Hopmans SN, Austin RC, Pinthus JH. Duivenvoorden WCM, et al. Among authors: Pinthus JH. Oncol Lett. 2017 May;13(5):3624-3630. doi: 10.3892/ol.2017.5908. Epub 2017 Mar 24. Oncol Lett. 2017. PMID: 28521463 Free PMC article.

Cite

Share